SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $3,910,995,502 |
| Positions | 44 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | COM | $555,315,165 | 2,965,160 |
| KYMERA THERAPEUTICS INC | KYMR | COM | $444,008,203 | 3,872,052 |
| XOMA ROYALTY CORPORATION | XOMA | COM NEW | $322,715,378 | 7,593,303 |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $311,544,999 | 16,001,284 |
| GH RESEARCH PLC | GHRS | ORDINARY SHARES | $232,516,247 | 8,650,158 |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $180,697,390 | 3,366,823 |
| NEKTAR THERAPEUTICS | NKTR | COM NEW | $166,920,946 | 2,391,075 |
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $123,629,081 | 1,056,027 |
| XENCOR INC | XNCR | COM | $114,852,892 | 7,133,720 |
| ALKERMES PLC | ALKS | SHS | $112,895,716 | 2,154,704 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.